SALT LAKE CITY, Oct. 10, 2017 -- Nu-Med Plus, Inc. (OTCBB:NUMD), a medical device company which investigates and develops applications of Nitric Oxide technologies in the medical field, has selected Franklin Innovation to complement their existing NU-MED team and development partners. This addition will enhance NU-MED’s ability to aggressively move forward with pursuing FDA submission of their Nitric Oxide Hospital unit.
Franklin Innovation is a successful results oriented development firm with proven performance in electronic design and system integration along with the experience and the technical resources for developing successful products.
Inhaled Nitric oxide is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns) and may have future applications for a variety of other diseases and complications that are currently being investigated. Commented Mr. Jeff Robins, President and CEO of Nu-Med-Plus. “We are excited to have Franklin Innovation join our existing team. Their expertise will help drive forward our project strategy to successfully submit and gain FDA approval for our Nitric Oxide hospital unit.”
About Nu-Med Plus, Inc.
Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com.
Contact:
Jeff Robins/President 801-746-3570
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.


Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 



